A

AprilBio Co Ltd
KOSDAQ:397030

Watchlist Manager
AprilBio Co Ltd
KOSDAQ:397030
Watchlist
Price: 15 390 KRW 2.19% Market Closed
Market Cap: 345.4B KRW
Have any thoughts about
AprilBio Co Ltd?
Write Note

AprilBio Co Ltd
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

AprilBio Co Ltd
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
A
AprilBio Co Ltd
KOSDAQ:397030
Net Income (Common)
-â‚©14.1B
CAGR 3-Years
-11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Net Income (Common)
â‚©187.1B
CAGR 3-Years
-30%
CAGR 5-Years
-5%
CAGR 10-Years
7%
SK Bioscience Co Ltd
KRX:302440
Net Income (Common)
â‚©22.3B
CAGR 3-Years
-12%
CAGR 5-Years
20%
CAGR 10-Years
N/A
H
Hugel Inc
KOSDAQ:145020
Net Income (Common)
â‚©112B
CAGR 3-Years
20%
CAGR 5-Years
18%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Net Income (Common)
â‚©88.8B
CAGR 3-Years
24%
CAGR 5-Years
36%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Net Income (Common)
-â‚©2.9B
CAGR 3-Years
51%
CAGR 5-Years
18%
CAGR 10-Years
N/A
No Stocks Found

AprilBio Co Ltd
Glance View

Market Cap
337.3B KRW
Industry
Biotechnology

AprilBio Co Ltd is a Korea-based company primarily engaged in the biological drug development business. The Company is primarily engaged in the bio-innovative new drug research and development (R&D) business such as antibody therapeutics and long-acting recombinant protein pharmaceuticals.

Intrinsic Value
16 570.57 KRW
Undervaluation 7%
Intrinsic Value
Price
A

See Also

What is AprilBio Co Ltd's Net Income (Common)?
Net Income (Common)
-14.1B KRW

Based on the financial report for Dec 31, 2023, AprilBio Co Ltd's Net Income (Common) amounts to -14.1B KRW.

What is AprilBio Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
-11%

Over the last year, the Net Income (Common) growth was -58%. The average annual Net Income (Common) growth rates for AprilBio Co Ltd have been -11% over the past three years .

Back to Top